Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD3/CD19 Depleted ASCT for SSc and SLE
NCT05029336Phase 2Recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). Primary endpoint: Progression-Free Survival at 2 years. Started Mar 2026; status: recruiting.
02
Conditions
systemic sclerosis (SSc)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05029336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029336.